Skip to main content

Search

Reset all filters
245 Result(s)
Sort by

Scleroderma Life Hacks

Scleroderma Life Hacks

Video series featuring people living with scleroderma using everyday items in different ways to help them manage their symptoms. Part of the global 'More Than Scleroderma' initiative developed by Boehringer Ingelheim, with support from patient organi
What are acute exacerbations in IPF?

What are acute exacerbations in IPF?

Risk factors for acute exacerbations in IPF are unclear, but there is evidence that a number of factors may increase risk. Learn more here.
Stroke, Don’t Stay at Home

Stroke, Don’t Stay at Home

During COVID-19, there was a decrease in stroke hospital admissions. Learn why it is crucial that patients can still access urgent care at this time.
Angels Initiative in South Africa

Angels Initiative in South Africa

Dr Stacey Rossouw explains how the Angels initiative is making a difference in South Africa and optimizing stroke care
Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease

Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease

EMPA-KIDNEY Phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease
Behind the Lab

Behind the Lab

Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.
Twynsta®

Twynsta®

Treatment of hypertension alone or with other antihypertensive agents. As initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals (USA). Add-on therapy in adult patients with not adequately co
Striverdi® Respimat®

Striverdi® Respimat®

Maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Giotrif®

Giotrif®

For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations. For the treatment of patients with locally advanced or metastatic NSCLC of squamous hist
Our Partners_ViraTherapeutics

Our Partners_ViraTherapeutics

Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.